Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CONy 2024 | Diagnostic utility of CSF biomarkers in patients with rapidly progressive dementia

Michael Geschwind, MD, PhD, FAAN, Memory and Aging Center, University of California, San Francisco, CA, discusses the diagnostic utility of cerebrospinal fluid (CSF) biomarkers in patients with rapidly progressive dementia (RPD), commenting on some of the most common proteins that have been used diagnostically in the past. Dr Geschwind goes on to describe the CSF real-time quaking-induced conversion (RT-QuIC) assay, which exploits the ability of pathological prion proteins present in a sample to induce misfolding and aggregation of normal prion protein, which can be monitored in real time using fluorescent dyes. Studies have found this method to have a high specificity and sensitivity; however, Dr Geschwind notes that around 15% of patients with prion disease will have a negative test result. This interview took place at the 18th Annual Congress on Controversies in Neurology (CONy 2024) in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.